Fatty liver screening
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Please help WikiDoc by adding content here. It’s easy! Click here to learn about editing.
Overview
Overview
Screening
Screening
Per the American Gastroenterological Association (AGA) in 2021[1], screening should be:
- Diabetes mellitus Type 2
- 2 or more metabolic risk factors (entral obesity, high triglycerides, low HDL cholesterol, hypertension, prediabetes, or insulin resistance)
- Excessive alcohol intake
- Steatosis on any imaging modality or elevated aminotransferases
Per the American Association for the Study of Liver Diseases (AASLD) in 2023[2]:
- “All patients with hepatic steatosis or clinically suspected NAFLD based on the presence of obesity and metabolic risk factors should undergo primary risk assessment with FIB-4.”
References
References
- ↑ Kanwal F, Shubrook JH, Adams LA, Pfotenhauer K, Wai-Sun Wong V, Wright E; et al. (2021). “Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease”. Gastroenterology. 161 (5): 1657–1669. doi:10.1053/j.gastro.2021.07.049. PMC 8819923 Check
|pmc=value (help). PMID 34602251 Check|pmid=value (help). - ↑ Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D; et al. (2023). “AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease”. Hepatology. doi:10.1097/HEP.0000000000000323. PMID 36727674 Check
|pmid=value (help).
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH